WuXi Biologics Hosts Basel CRDMO+ Day for More Than 100 Industry Leaders and Experts

By Public Technologies
  • WuXi Biologics hosted its third annual Basel CRDMO+ Day during Festival of Biologics Basel 2026, drawing more than 100 industry leaders.
  • Annual development capacity will expand to approximately 300 investigational new drug programs and 20 biologics license application programs by 2027.
  • Bispecific antibodies or antibody-drug conjugates accounted for 71% of 169 projects added in the first half of 2026.
  • The global manufacturing network exceeds 600,000 liters of planned bioreactor capacity, with approximately half outside China.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wuxi Biologics (Cayman) Inc. published the original content used to generate this news brief on October 19, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk